for the quality of the registered data. Some of the problems identified with the quality of registered data may therefore be solved by having a named PI in the registry record. Arguably the two most important pieces of information about a clinical trial that need to be registered are the description of the interventions being compared, and the outcomes upon which any conclusion about the safety and effectiveness of the interventions will be made. As demonstrated by this and previous studies, the quality of this information, as it has been registered to date, has been poor [27] , [30] -- [36] . In 2005, nine to ten percent of registered trial records on ClinicalTrials.gov provided an incomplete or nonspecific description of the intervention name [30] , [33] . Although subsequent studies suggest that this has improved to less than two or three percent [33] , [34] , [46] , more information is required about the intervention than the name. There should also be a description that is detailed enough for it to be possible to distinguish between the arms of the study. For trials of drugs, biologicals and vaccines this means information on the dose, frequency, route of administration and duration of treatment [25] , [47] . In the current study less than half of the intervention arms where this information was relevant provided it. That there is room for improvement is confirmed by the fact that records of some trials (Phase 0 and I) describe interventions in greater detail,